Literature DB >> 1883126

When should patients with lethal ventricular arrhythmia resume driving? An analysis of state regulations and physician practices.

S A Strickberger1, C O Cantillon, P L Friedman.   

Abstract

Most states have specific laws governing whether patients with seizure disorders can drive. To learn whether similar laws exist for patients with lethal ventricular arrhythmias, we surveyed the Departments of Motor Vehicles in all 50 states. In addition, either an arrhythmia specialist (n = 25) or a general cardiologist (n = 25) was chosen randomly from each state and interviewed to study physician awareness of such laws and physician attitudes toward driving by patients with arrhythmias. Forty-two states (84%) have laws restricting driving by patients who have seizures; only 8 states (16%) have specific laws for patients with arrhythmias. No state makes a distinction between driving by patients with arrhythmias who are managed with an implantable cardioverter-defibrillator (ICD) compared with patients who are managed medically. Seventy-four percent of physicians did not know their own state's laws about driving by patients who have ventricular arrhythmias. Cardiologists were more likely to advise no driving restriction for medically treated patients than for ICD-treated patients. Cardiologists were also more likely to advise permanent restriction for patients with ICDs than for patients treated medically. We conclude that greater legal and medical consensus is needed to guide physicians in advising patients with lethal ventricular arrhythmias about driving restrictions.

Entities:  

Mesh:

Year:  1991        PMID: 1883126     DOI: 10.7326/0003-4819-115-7-560

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  1 in total

1.  Cardiac rehabilitation/exercise in patients with implantable cardioverter defibrillators.

Authors:  A W Friedman; R C Lipman; S J Silver; R A Minella; J L Hoover
Journal:  J Natl Med Assoc       Date:  1996-06       Impact factor: 1.798

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.